Department of Pharmacy, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
Department of Pharmacy, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
Int Immunopharmacol. 2023 Aug;121:110495. doi: 10.1016/j.intimp.2023.110495. Epub 2023 Jun 20.
The incidence of allergic disease significantly increases in recent decades, causing it become a major public health problem all over the world. The common allergic diseases such as allergic dermatitis, allergy rhinitis, allergic asthma and food allergy are mediated, at least in part, by immunoglobulin E (IgE), and so IgE acts as a central role in allergic diseases. IgE can interact with its high-affinity receptor (FcεRⅠ) which is primarily expressed on tissue-resident mast cells and circulating basophils, initiating intracellular signal transduction and then causing the activation and degranulation of mast cells and basophils. On the other hand, IgE interaction with its low-affinity receptor (CD23), can regulate various IgE-mediated immune responses including IgE-allergen complex presentation, IgE synthesis, the growth and differentiation of both B and T cells, and the secretion of pro-inflammatory mediators. With the deeper mechanism research for allergic diseases, new therapeutic strategies for interfering IgE are developed and receive a great attention. In this review, we summarize a current profile of therapeutic strategies for interfering IgE in allergic diseases. Besides, we suggest that targeting memory B cells (including long-lived plasma cells and (or) IgE memory B cells) may help to completely control allergic diseases, and highlight that the development of drugs synergistically aiming to multiple targets can be a better choice for improving treatment efficacy which results from allergic diseases as the systemic disorders caused by an impaired immune system.
在过去的几十年里，过敏疾病的发病率显著增加，使其成为全世界主要的公共卫生问题。常见的过敏疾病，如过敏性皮炎、过敏鼻炎、过敏性哮喘和食物过敏，至少部分是由免疫球蛋白 E（IgE）介导的，因此 IgE 在过敏疾病中起着核心作用。IgE 可以与其高亲和力受体（FcεRⅠ）相互作用，该受体主要表达在组织驻留的肥大细胞和循环嗜碱性粒细胞上，启动细胞内信号转导，然后导致肥大细胞和嗜碱性粒细胞的激活和脱颗粒。另一方面，IgE 与低亲和力受体（CD23）相互作用，可以调节各种 IgE 介导的免疫反应，包括 IgE-过敏原复合物的呈递、IgE 的合成、B 和 T 细胞的生长和分化，以及促炎介质的分泌。随着对过敏疾病机制的深入研究，开发了干扰 IgE 的新治疗策略，并受到了极大的关注。在这篇综述中，我们总结了目前用于干预过敏疾病中 IgE 的治疗策略。此外，我们认为针对记忆 B 细胞（包括长寿浆细胞和（或）IgE 记忆 B 细胞）可能有助于完全控制过敏疾病，并强调针对多个靶点的药物协同开发可能是改善过敏疾病治疗效果的更好选择，因为过敏疾病是由免疫系统受损引起的全身性疾病。
